Citations 22
Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey
Yoshida, Akira , Kim, Minchul , Kuwana, Masataka , Ravichandran, Naveen , Makol, Ashima , Sen, Parikshit , Agarwal, Vishwesh , Kardeş, Sinan , Day, Jessica , Milchert, Marcin , Joshi, Mrudula , Salim, Babur , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Parodis, Ioannis , Selva-O’Callaghan, Albert , Nikiphorou, Elena , Chatterjee, Tulika , Tan, Ai Lyn , Nune, Arvind , Ziadé, Nelly , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manesh, Manoj M, Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Pandey, Arun Kumar R, Pauling, John D , Sambataro, Gianluca , Atzeni, Fabiola , Govoni, Marcello, Bocci, Elena Bartoloni, Orsolini, Giovanni , Danielli, Maria Giovanna, Tehozol, Erick Adrian Zamora , Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos , Aharonov, Or, Maurier, F. , Meyer, Alain, Nagy‐Vincze, Melinda , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Hudson, Marie , Landon‐Cardinal, Océane , Shaharir, Syahrul Sazliyana , Zuleta, Wilmer Gerardo Rojas, Silva, José António Pereira, Gupta, Latika , Lilleker, James B , Day, Jessica , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Selva O'Callaghan, Albert , Tan, Ai Lyn , Nune, Arvind , Ziade, Nelly , Knitza, Johannes , Distler, Oliver , Chinoy, Hector , Gupta, Latika , Milchert, Marcin , Agarwal, Vikas , Joshi, Mrudula , Agarwal, Vishwesh , Kim, Minchul , Makol, Ashima , Velikova, Tsvetelina , Chatterjee, Tulika , Pauling, John D , Naveen, R , Zamora Tehozol, Erick Adrian , Sen, Parikshit , Yoshida, Akira , Singh, Yogesh Preet , Gheita, Tamer A. , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Barman, Bhupen , Ranjan, Rajiv , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Chandwar, Kunal , Cansu, Döndü Üsküdar , Wincup, Chris , Papa, Nicoletta Del , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Angelis, Rossella De , Venerito, Vincenzo , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Rojas Serrano, Jorge , Torre, Ignacio García‐De La , Gil‐Vila, Albert , Gonzalez, Raquel Aranega, Kimura, Naoki, Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Hoff, Leonardo Santos , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena
Rheumatology | August 3, 2022 | Volume: 62 | Issue: 3 | Pages: 1204-1215
AbstractObjectivesThe assessment of physical function is fundamental in the management of patients with idiopathic inflammatory myopathies (IIMs). We aimed to investigate the physical function of patients with IIMs compared with those with non-IIM autoimmune rheumatic diseases (AIRDs) utilizing Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function (PF) data obtained in the COVAD study, an international self-reported e-survey assessing the safety of COVID-19 vaccines in AIRDs.MethodsDemographics, AIRD diagnosis, disease activity, and PROMIS PF short form-10a data were extracted from the COVAD database. PROMIS PF-10a scores were compared between disease categories and stratified by disease activity. Factors affecting PROMIS PF-10a scores other than disease activity were identified by multivariable regression analysis in patients with inactive disease.ResultsA total of 1057 IIM patients, 3635 non-IIM AIRD patients and 3981 healthy controls (HCs) responded to the COVAD e-survey from April to August 2021. Using a binomial regression model, the predicted mean of PROMIS PF-10a scores was significantly lower in IIM patients compared with non-IIM AIRD patients or HCs [36.3 (95% CI 35.5, 37.1) vs 41.3 (95% CI 40.2, 42.5) vs 46.2 (95% CI 45.8, 46.6), P < 0.001], irrespective of disease activity. The independent factors for lower PROMIS PF-10a scores in patients with inactive disease were older age, female, longer disease duration, and a diagnosis of inclusion body myositis or polymyositis.ConclusionPhysical function is significantly impaired in IIMs compared with non-IIM AIRDs or HCs, even in patients with inactive disease. Our study highlights a critical need for better strategies to minimize functional disability in patients with IIMs.
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
Gil‐Vila, Albert , Ravichandran, Naveen , Selva-O’Callaghan, Albert , Sen, Parikshit , Nune, Arvind , Gaur, Prithvi Sanjeevkumar , Joshi, Mrudula , Agarwal, Vishwesh , Kardeş, Sinan , Kim, Minchul , Day, Jessica , Milchert, Marcin , Salim, Babur , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Chatterjee, Tulika , Ziadé, Nelly , Kuwana, Masataka , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Needham, Merrilee , Loarce‐Martos, Jesus , Ordóñez, Andrea Bran , Gupta, Latika , Lilleker, James B , Joshi, Mrudula , Agarwal, Vishwesh , Kardes, Sinan , Kim, Minchul , Day, Jessica , Makol, Ashima , Milchert, Marcin , Gheita, Tamer , Salim, Babur , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Chatterjee, Tulika , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Knitza, Johannes , Kuwana, Masataka , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Selva O'Callaghan, Albert , Nune, Arvind , Naveen, R , Sen, Parikshit , Singh, Yogesh Preet , Gonzalez, Raquel Arànega, Makol, Ashima , Gheita, Tamer A. , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study
Muscle & Nerve | July 23, 2022 | Volume: 66 | Issue: 4 | Pages: 426-437
AbstractIntroduction/AimsIn this study we investigated COVID‐19 vaccination–related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs).MethodsSeven‐day vaccine ADEs were collected in an international patient self‐reported e‐survey. Descriptive statistics were obtained and multivariable regression was performed.ResultsTen thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30‐455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76.3% of the IIM patients and 4.6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2.7; interquartile range [IQR], 1.04‐7.3) and minor (OR, 1.5; IQR, 1.1‐2.2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2.3; IQR, 1.2‐4.2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1.9; IQR, 1.1‐3.3; and OR, 2.2; IQR, 1.1‐4.3, respectively). Overall, ADEs were less frequent in inclusion‐body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients.DiscussionSeven‐day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID‐19 through vaccination likely outweighs the risk of vaccine‐related ADEs. Our results may inform future guidelines regarding COVID‐19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long‐term outcomes and disease flares are needed to shed more light on developing future COVID‐19 vaccination guidelines.